EUVIMEDΑνακαλύψτε το EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen access

Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)

Katell Le Dû iD, Adrien Chauchet iD, Sophie Sadot-Lebouvier iD, Olivier Fitoussi iD, Bijou Fontanet iD, Arnaud Saint-Lezer iD, Frédéric Maloisel iD, Cédric Rossi iD, Sylvain Carras iD, Anne Parcelier iD, Magali Balavoine iD, Anne-Lise Septans iD

JMIR Cancer · 2025

DOI: 10.2196/65960 ↗

At a glance

Randomisierte kontrollierte Studie in JMIR Cancer, 2025. Written by Katell Le Dû and 11 co-authors. Institution: Department of Hematology, Confluent Private Hospital, 2 rue Eric Tabarly, Nantes, 44277, France, 33 0615246067. Major MEDLINE topics: Lymphoma, Neoplasm Recurrence, Local. Cited 1 times so far (Crossref); 30 references. The full text is freely available in PubMed Central.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Background

Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse.

Objective

This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire.

Methods

We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis.

Results

A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm ( P =.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm ( P

Subjects

MeSH terms (MEDLINE)

LymphomaNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedProspective StudiesAgedAdultSurveys and QuestionnairesQuality of LifeFollow-Up StudiesInternetPatient Reported Outcome Measures

Author keywords

Hodgkin lymphomaT-cell lymphomadetectionlymphomapatient-reported outcome measuresprogressionquality of liferandomized trialrelapserisk of relapsesurvivalweb-based

Authors and institutions

  • Department of Hematology, Confluent Private Hospital, 2 rue Eric Tabarly, Nantes, 44277, France, 33 0615246067.
  • Department of Hematology, University Hospital, Besançon, France.
  • Department of Hematology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
  • Department of Hematology, Bergonié Institute, Bordeaux, France.
  • Department of Hematology, Mont de Marsan Hospital, Mont de Marsan, France.
  • Department of Hematology, Clinique Saint-Anne, Strasbourg, France.

ORCID profiles: Katell Le Dû, Adrien Chauchet, Sophie Sadot-Lebouvier, Olivier Fitoussi, Bijou Fontanet, Arnaud Saint-Lezer, Frédéric Maloisel, Cédric Rossi, Sylvain Carras, Anne Parcelier, Magali Balavoine, Anne-Lise Septans

Cite

APA

Le Dû, K., Chauchet, A., Sadot-Lebouvier, S., Fitoussi, O., Fontanet, B., Saint-Lezer, A., Maloisel, F., Rossi, C., Carras, S., Parcelier, A., Balavoine, M., & Septans, A. L. (2025). Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). JMIR Cancer. https://doi.org/10.2196/65960

Vancouver

Le Dû K, Chauchet A, Sadot-Lebouvier S, Fitoussi O, Fontanet B, Saint-Lezer A, et al. Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). JMIR Cancer. 2025. doi:10.2196/65960

BibTeX
@article{LeD2025,
  author = {Le Dû, Katell and Chauchet, Adrien and Sadot-Lebouvier, Sophie and Fitoussi, Olivier and Fontanet, Bijou and Saint-Lezer, Arnaud and Maloisel, Frédéric and Rossi, Cédric and Carras, Sylvain and Parcelier, Anne and Balavoine, Magali and Septans, Anne-Lise},
  title = {Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)},
  journal = {JMIR Cancer},
  year = {2025},
  doi = {10.2196/65960}
}
Start for free →